Drug Pricing & Reimbursement

Once a drug product receives regulatory approval from Health Canada, market access and pricing continue to be critical issues for manufacturers in Canada. Pricing is effectively controlled at two levels: the Patented Medicine Prices Review Board (PMPRB) exerts direct pricing controls over patented medicines; and the provinces and territories exert considerable pricing pressures on manufacturers through a labyrinth of reimbursement and interchangeability rules.

MBM’s experienced team of professionals provide the necessary expertise to help their clients strategically and successfully navigate through the complex patchwork of legislation, review bodies and private/public drug plans across the country to ensure that their products are marketed in a timely and profitable manner.